SK Bioscience start to deliver Novavax COVID-19 vaccine

South Korea's SK Bioscience Co. announced on Tuesday that it started to deliver the Novavax COVID-19 vaccine against XBB.1.5 variant.

According to Novavax, this vaccine is the only one approved as an updated protein-based non-mRNA COVID-19 vaccine against XBB.1.5, XBB.1.16, and XBB.2.3 variants.

SK Bioscience received a license for Novavax COVID-19 vaccine for emergency use authorization from the Ministry of Food and Drug Safety on Nov. 29. for people aged 12 and older.

In August, SK Bioscience extended its licensing agreement with Novavax, securing exclusive rights for the supply and production of this vaccine in South Korea and non-exclusive distribution rights in Thailand and Vietnam.

Write to Ji-Hyun Lee at bluesky@hankyung.com